Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of gimatecan capsules in platinum-resistant recurrent or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer
CTR20211176Phase 2Active
- Sponsor
- Zhaoke Ophthalmology
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gimatecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Zhaoke Ophthalmology. Started Aug 2021; status: active.
02
Drugs
gimatecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20211176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211176.